Skip to main content
Top
Published in: Cardiovascular Diabetology 1/2012

Open Access 01-12-2012 | Original investigation

Angiotensin-converting enzyme inhibition and food restriction in diabetic mice do not correct the increased sensitivity for ischemia-reperfusion injury

Authors: Gerry Van der Mieren, Ines Nevelsteen, Annelies Vanderper, Wouter Oosterlinck, Willem Flameng, Paul Herijgers

Published in: Cardiovascular Diabetology | Issue 1/2012

Login to get access

Abstract

Background

The number of patients with diabetes or the metabolic syndrome reaches epidemic proportions. On top of their diabetic cardiomyopathy, these patients experience frequent and severe cardiac ischemia-reperfusion (IR) insults, which further aggravate their degree of heart failure. Food restriction and angiotensin-converting enzyme inhibition (ACE-I) are standard therapies in these patients but the effects on cardiac IR injury have never been investigated. In this study, we tested the hypothesis that 1° food restriction and 2° ACE-I reduce infarct size and preserve cardiac contractility after IR injury in mouse models of diabetes and the metabolic syndrome.

Methods

C57Bl6/J wild type (WT) mice, leptin deficient ob/ob (model for type II diabetes) and double knock-out (LDLR-/-;ob/ob, further called DKO) mice with combined leptin and LDL-receptor deficiency (model for metabolic syndrome) were used. The effects of 12 weeks food restriction or ACE-I on infarct size and load-independent left ventricular contractility after 30 min regional cardiac ischemia were investigated. Differences between groups were analyzed for statistical significance by Student’s t-test or factorial ANOVA followed by a Fisher’s LSD post hoc test.

Results

Infarct size was larger in ob/ob and DKO versus WT. Twelve weeks of ACE-I improved pre-ischemic left ventricular contractility in ob/ob and DKO. Twelve weeks of food restriction, with a weight reduction of 35-40%, or ACE-I did not reduce the effect of IR.

Conclusion

ACE-I and food restriction do not correct the increased sensitivity for cardiac IR-injury in mouse models of type II diabetes and the metabolic syndrome.
Appendix
Available only for authorised users
Literature
1.
go back to reference Kereiakes DJ, Willerson JT: Metabolic syndrome epidemic. Circulation. 2003, 108: 1552-1553. 10.1161/01.CIR.0000093203.00632.2B.CrossRefPubMed Kereiakes DJ, Willerson JT: Metabolic syndrome epidemic. Circulation. 2003, 108: 1552-1553. 10.1161/01.CIR.0000093203.00632.2B.CrossRefPubMed
2.
go back to reference Wild S, Roglic G, Green A, Sicree R, King H: Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. Diabetes Care. 2004, 27: 1047-1053. 10.2337/diacare.27.5.1047.CrossRefPubMed Wild S, Roglic G, Green A, Sicree R, King H: Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. Diabetes Care. 2004, 27: 1047-1053. 10.2337/diacare.27.5.1047.CrossRefPubMed
3.
go back to reference Dohi T, Miyauchi K, Kasai T, Kajimoto K, Kubota N, Tamura H, Yokoyama T, Kojima T, Yokoyama K, Kurata T, Daida H: Impact of metabolic syndrome on 10-year clinical outcomes among patients with acute coronary syndrome. Circ J. 2009, 73: 1454-1458. 10.1253/circj.CJ-08-1122.CrossRefPubMed Dohi T, Miyauchi K, Kasai T, Kajimoto K, Kubota N, Tamura H, Yokoyama T, Kojima T, Yokoyama K, Kurata T, Daida H: Impact of metabolic syndrome on 10-year clinical outcomes among patients with acute coronary syndrome. Circ J. 2009, 73: 1454-1458. 10.1253/circj.CJ-08-1122.CrossRefPubMed
4.
go back to reference Haffner SM, Lehto S, Rönnemaa T, Pyörälä K, Laakso M: Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med. 1998, 339: 229-234. 10.1056/NEJM199807233390404.CrossRefPubMed Haffner SM, Lehto S, Rönnemaa T, Pyörälä K, Laakso M: Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med. 1998, 339: 229-234. 10.1056/NEJM199807233390404.CrossRefPubMed
5.
go back to reference Marfella R, Di Filippo C, Esposito K, Nappo F, Piegari E, Cuzzocrea S, Berrino L, Rossi F, Giugliano D, D'Amico M: Absence of inducible nitric oxide synthase reduces myocardial damage during ischemia reperfusion in streptozotocin-induced hyperglycemic mice. Diabetes. 2004, 53: 454-462. 10.2337/diabetes.53.2.454.CrossRefPubMed Marfella R, Di Filippo C, Esposito K, Nappo F, Piegari E, Cuzzocrea S, Berrino L, Rossi F, Giugliano D, D'Amico M: Absence of inducible nitric oxide synthase reduces myocardial damage during ischemia reperfusion in streptozotocin-induced hyperglycemic mice. Diabetes. 2004, 53: 454-462. 10.2337/diabetes.53.2.454.CrossRefPubMed
6.
go back to reference Aasum E, Hafstad AD, Severson DL, Larsen TS: Age-dependent changes in metabolism, contractile function and ischemic sensitivity in hearts from db/db mice. Diabetes. 2003, 52: 434-441.CrossRefPubMed Aasum E, Hafstad AD, Severson DL, Larsen TS: Age-dependent changes in metabolism, contractile function and ischemic sensitivity in hearts from db/db mice. Diabetes. 2003, 52: 434-441.CrossRefPubMed
7.
go back to reference Bouhidel O, Pons S, Souktani R, Zini R, Berdeaux A, Ghaleh B: Myocardial ischemic postconditioning against ischemia-reperfusion is impaired in ob/ob mice. Am J Physiol Heart Circ Physiol. 2008, 295: H1580-H1586. 10.1152/ajpheart.00379.2008.PubMedCentralCrossRefPubMed Bouhidel O, Pons S, Souktani R, Zini R, Berdeaux A, Ghaleh B: Myocardial ischemic postconditioning against ischemia-reperfusion is impaired in ob/ob mice. Am J Physiol Heart Circ Physiol. 2008, 295: H1580-H1586. 10.1152/ajpheart.00379.2008.PubMedCentralCrossRefPubMed
8.
go back to reference Van den Bergh A, Vanderper A, Vangheluwe P, Desjardins F, Nevelsteen I, Verreth W, Wuytack F, Holvoet P, Flameng W, Balligand JL, Herijgers P: Dyslipidemia in type II diabetic mice does not aggravate contractile impairment but increases ventricular stiffness. Cardiovasc Res. 2008, 77: 371-379.CrossRefPubMed Van den Bergh A, Vanderper A, Vangheluwe P, Desjardins F, Nevelsteen I, Verreth W, Wuytack F, Holvoet P, Flameng W, Balligand JL, Herijgers P: Dyslipidemia in type II diabetic mice does not aggravate contractile impairment but increases ventricular stiffness. Cardiovasc Res. 2008, 77: 371-379.CrossRefPubMed
9.
go back to reference Van den Bergh A, Flameng W, Herijgers P: Type II diabetic mice exhibit contractile dysfunction but maintain cardiac output by favourable loading conditions. Eur J Heart Fail. 2006, 8: 777-783. 10.1016/j.ejheart.2006.03.001.CrossRefPubMed Van den Bergh A, Flameng W, Herijgers P: Type II diabetic mice exhibit contractile dysfunction but maintain cardiac output by favourable loading conditions. Eur J Heart Fail. 2006, 8: 777-783. 10.1016/j.ejheart.2006.03.001.CrossRefPubMed
10.
go back to reference Buse JB, Ginsberg HN, Bakris GL, Clark NG, Costa F, Eckel R, Fonseca V, Gerstein HC, Grundy S, Nesto RW, Pignone MP, Plutzky J, Porte D, Redberg R, Stitzel KF, Stone NJ, American Heart Association American Diabetes Association, American Heart Association American Diabetes Association: Primary prevention of cardiovascular disease in people with diabetes mellitus. A Scientific statement from the American Heart Association and the American Diabetes Association. Circulation. 2007, 115: 114-126.CrossRefPubMed Buse JB, Ginsberg HN, Bakris GL, Clark NG, Costa F, Eckel R, Fonseca V, Gerstein HC, Grundy S, Nesto RW, Pignone MP, Plutzky J, Porte D, Redberg R, Stitzel KF, Stone NJ, American Heart Association American Diabetes Association, American Heart Association American Diabetes Association: Primary prevention of cardiovascular disease in people with diabetes mellitus. A Scientific statement from the American Heart Association and the American Diabetes Association. Circulation. 2007, 115: 114-126.CrossRefPubMed
11.
go back to reference Verreth W, De Keyzer D, Pelat M, Verhamme P, Ganame J, Bielicki JK, Mertens A, Quarck R, Benhabiles N, Marguerie G, Mackness B, Mackness M, Ninio E, Herregods MC, Balligand JL, Holvoet P: Weight-loss-associated induction of peroxisome proliferator-activated receptor-alpha and peroxisome proliferator-activated receptor-gamma correlate with reduced atherosclerosis and improved cardiovascular function in obese insulin-resistant mice. Circulation. 2004, 110: 3259-3269. 10.1161/01.CIR.0000147614.85888.7A.CrossRefPubMed Verreth W, De Keyzer D, Pelat M, Verhamme P, Ganame J, Bielicki JK, Mertens A, Quarck R, Benhabiles N, Marguerie G, Mackness B, Mackness M, Ninio E, Herregods MC, Balligand JL, Holvoet P: Weight-loss-associated induction of peroxisome proliferator-activated receptor-alpha and peroxisome proliferator-activated receptor-gamma correlate with reduced atherosclerosis and improved cardiovascular function in obese insulin-resistant mice. Circulation. 2004, 110: 3259-3269. 10.1161/01.CIR.0000147614.85888.7A.CrossRefPubMed
12.
go back to reference Crandall DL, Goldstein BM, Gabel RA, Cervoni P: Hemodynamic effects of weight reduction in the obese rat. Am J Physiol. 1984, 247: R266-R271.PubMed Crandall DL, Goldstein BM, Gabel RA, Cervoni P: Hemodynamic effects of weight reduction in the obese rat. Am J Physiol. 1984, 247: R266-R271.PubMed
13.
go back to reference Broderick TL, Belke T, Driedzic WR: Effects of chronic caloric restriction on mitochondrial respiration in the ischemic reperfused rat heart. Mol Cell Biochem. 2002, 233: 119-125. 10.1023/A:1015506327849.CrossRefPubMed Broderick TL, Belke T, Driedzic WR: Effects of chronic caloric restriction on mitochondrial respiration in the ischemic reperfused rat heart. Mol Cell Biochem. 2002, 233: 119-125. 10.1023/A:1015506327849.CrossRefPubMed
14.
go back to reference Velasquez MT, Bhathena SJ, Striffler JS, Thibault N, Scalbert E: Role of angiotensin-converting enzyme inhibition in glucose metabolism and renal injury in diabetes. Metabolism. 1998, 47: 7-11.CrossRefPubMed Velasquez MT, Bhathena SJ, Striffler JS, Thibault N, Scalbert E: Role of angiotensin-converting enzyme inhibition in glucose metabolism and renal injury in diabetes. Metabolism. 1998, 47: 7-11.CrossRefPubMed
15.
go back to reference ACE Inhibitor Myocardial Infarction Collaborative Group: Indications for ACE inhibitors in the early treatment of acute myocardial infarction: systematic overview of individual data from 100,000 patients in randomized trials. Circulation. 1998, 97: 2202-2212.CrossRef ACE Inhibitor Myocardial Infarction Collaborative Group: Indications for ACE inhibitors in the early treatment of acute myocardial infarction: systematic overview of individual data from 100,000 patients in randomized trials. Circulation. 1998, 97: 2202-2212.CrossRef
16.
go back to reference Mehta PM, Przyklenk K, Kloner RA: Cardioprotective effects of captopril in myocardial ischemia, ischemia/reperfusion and infarction. Eur Heart J. 1990, 11: 94-99.CrossRefPubMed Mehta PM, Przyklenk K, Kloner RA: Cardioprotective effects of captopril in myocardial ischemia, ischemia/reperfusion and infarction. Eur Heart J. 1990, 11: 94-99.CrossRefPubMed
17.
go back to reference Parlakpinar H, Ozer MK, Acet A: Effects of captopril and angiotensin II receptor blockers (AT1, AT2) on myocardial ischemia-reperfusion induced infarct size. Cytokine. 2011, 56: 688-694. 10.1016/j.cyto.2011.09.002.CrossRefPubMed Parlakpinar H, Ozer MK, Acet A: Effects of captopril and angiotensin II receptor blockers (AT1, AT2) on myocardial ischemia-reperfusion induced infarct size. Cytokine. 2011, 56: 688-694. 10.1016/j.cyto.2011.09.002.CrossRefPubMed
18.
go back to reference Yang X-P, Liu Y-H, Shesely EG, Bulagannawar M, Liu F, Carretero OA: Endothelial nitric oxide gene knock-out mice: cardiac phenotypes and the effect of angiotensin-converting enzyme inhibitor on myocardial ischemia/reperfusion injury. Hypertension. 1999, 34: 24-30. 10.1161/01.HYP.34.1.24.CrossRefPubMed Yang X-P, Liu Y-H, Shesely EG, Bulagannawar M, Liu F, Carretero OA: Endothelial nitric oxide gene knock-out mice: cardiac phenotypes and the effect of angiotensin-converting enzyme inhibitor on myocardial ischemia/reperfusion injury. Hypertension. 1999, 34: 24-30. 10.1161/01.HYP.34.1.24.CrossRefPubMed
19.
go back to reference Liu YH, Yang XP, Sharov VG, Sigmon DH, Sabbath HN, Carretero OA: Paracrine systems in the cardioprotective effect of angiotensin-converting enzyme inhibitors on myocardial ischemia/reperfusion injury in rats. Hypertension. 1996, 27: 7-13. 10.1161/01.HYP.27.1.7.CrossRefPubMed Liu YH, Yang XP, Sharov VG, Sigmon DH, Sabbath HN, Carretero OA: Paracrine systems in the cardioprotective effect of angiotensin-converting enzyme inhibitors on myocardial ischemia/reperfusion injury in rats. Hypertension. 1996, 27: 7-13. 10.1161/01.HYP.27.1.7.CrossRefPubMed
20.
go back to reference Nozawa Y, Miura T, Tsuchida A, Kita H, Fukuma T, Shimamoto K: Chronic treatment with an ACE inhibitor, temocapril, lowers the threshold for the infarct size-limiting effect of ischemic preconditioning. Cardiovac Drugs Ther. 1999, 13: 151-157. 10.1023/A:1007744428819.CrossRef Nozawa Y, Miura T, Tsuchida A, Kita H, Fukuma T, Shimamoto K: Chronic treatment with an ACE inhibitor, temocapril, lowers the threshold for the infarct size-limiting effect of ischemic preconditioning. Cardiovac Drugs Ther. 1999, 13: 151-157. 10.1023/A:1007744428819.CrossRef
21.
go back to reference Itoh S, Ding B, Shishido T, Lerner-Marmarosh N, Wang N, Maekawa N, Berk BC, Takeishi Y, Yan C, Blaxall BC, Abe J: Role of p90 ribosomal S6 kinase-mediated prorenin-converting enzyme in ischemic and diabetic myocardium. Circulation. 2006, 113: 1787-1798. 10.1161/CIRCULATIONAHA.105.578278.CrossRefPubMed Itoh S, Ding B, Shishido T, Lerner-Marmarosh N, Wang N, Maekawa N, Berk BC, Takeishi Y, Yan C, Blaxall BC, Abe J: Role of p90 ribosomal S6 kinase-mediated prorenin-converting enzyme in ischemic and diabetic myocardium. Circulation. 2006, 113: 1787-1798. 10.1161/CIRCULATIONAHA.105.578278.CrossRefPubMed
22.
go back to reference Wichi R, Farah V, Chen Y, Irigoyen MC, Morris M: Deficiency in angiotensin AT1a receptors prevents diabetes-induced hypertension. Am J Physiol Regul Integr Comp Physiol. 2007, 292: R1184-R1189.CrossRefPubMed Wichi R, Farah V, Chen Y, Irigoyen MC, Morris M: Deficiency in angiotensin AT1a receptors prevents diabetes-induced hypertension. Am J Physiol Regul Integr Comp Physiol. 2007, 292: R1184-R1189.CrossRefPubMed
23.
go back to reference Van der Mieren G, Van den Bergh A, Nevelsteen I, Vanderper A, Flameng W, Herijgers P: Hypoxic preconditioning preserves cardiac contractility and reduces infarct size in vivo. The Open Surgery Journal. 2008, 2: 24-29. 10.2174/1874300500802010024.CrossRef Van der Mieren G, Van den Bergh A, Nevelsteen I, Vanderper A, Flameng W, Herijgers P: Hypoxic preconditioning preserves cardiac contractility and reduces infarct size in vivo. The Open Surgery Journal. 2008, 2: 24-29. 10.2174/1874300500802010024.CrossRef
24.
go back to reference Van den Bergh A, Flameng W, Herijgers P: Parameters of ventricular contractility in mice: influence of load and sensitivity to changes in inotropic state. Pflugers Arch. 2008, 455: 987-994. 10.1007/s00424-007-0362-8.CrossRefPubMed Van den Bergh A, Flameng W, Herijgers P: Parameters of ventricular contractility in mice: influence of load and sensitivity to changes in inotropic state. Pflugers Arch. 2008, 455: 987-994. 10.1007/s00424-007-0362-8.CrossRefPubMed
25.
go back to reference Rodrigues B, Rosa KT, Medeiros A, Schaan BD, Brum PC, De Angelis K, Irigoyen MC: Hyperglycemia can delay left ventricular dysfunction but not autonomic damage after myocardial infarction in rodents. Cardiovasc Diabetol. 2011, 10: 26-10.1186/1475-2840-10-26.PubMedCentralCrossRefPubMed Rodrigues B, Rosa KT, Medeiros A, Schaan BD, Brum PC, De Angelis K, Irigoyen MC: Hyperglycemia can delay left ventricular dysfunction but not autonomic damage after myocardial infarction in rodents. Cardiovasc Diabetol. 2011, 10: 26-10.1186/1475-2840-10-26.PubMedCentralCrossRefPubMed
26.
go back to reference Miki T, Itoh T, Sunaga D, Miura T: Effects of diabetes on myocardial infarct size and cardioprotection by preconditioning and postconditioning. Cardiovasc Diabetol. 2012, 11: 67-10.1186/1475-2840-11-67.PubMedCentralCrossRefPubMed Miki T, Itoh T, Sunaga D, Miura T: Effects of diabetes on myocardial infarct size and cardioprotection by preconditioning and postconditioning. Cardiovasc Diabetol. 2012, 11: 67-10.1186/1475-2840-11-67.PubMedCentralCrossRefPubMed
27.
go back to reference Wölkart G, Pang X, Stessel H, Kirchengast M, Brunner F: Chronic endothelin-A receptor antagonism is as protective as angiotensin converting enzyme inhibition against cardiac dysfunction in diabetic rats. Br J Pharmacol. 2007, 151: 1187-1197.PubMedCentralCrossRefPubMed Wölkart G, Pang X, Stessel H, Kirchengast M, Brunner F: Chronic endothelin-A receptor antagonism is as protective as angiotensin converting enzyme inhibition against cardiac dysfunction in diabetic rats. Br J Pharmacol. 2007, 151: 1187-1197.PubMedCentralCrossRefPubMed
28.
go back to reference Rui T, Zhang J, Xu X, Yao Y, Kao R, Martin M: Reduction of IL-33 expression exaggerates ischemia/reperfusion-induced myocardial injury in mice with diabetes mellitus. Cardiovasc Res. 2012, 94: 370-378. 10.1093/cvr/cvs015.CrossRefPubMed Rui T, Zhang J, Xu X, Yao Y, Kao R, Martin M: Reduction of IL-33 expression exaggerates ischemia/reperfusion-induced myocardial injury in mice with diabetes mellitus. Cardiovasc Res. 2012, 94: 370-378. 10.1093/cvr/cvs015.CrossRefPubMed
29.
go back to reference Abozguia K, Clarke K, Lee L, Frenneaux M: Modification of myocardial substrate use as a therapy for heart failure. Nat Clin Pract Cardiovasc Med. 2006, 3: 490-498. 10.1038/ncpcardio0583.CrossRefPubMed Abozguia K, Clarke K, Lee L, Frenneaux M: Modification of myocardial substrate use as a therapy for heart failure. Nat Clin Pract Cardiovasc Med. 2006, 3: 490-498. 10.1038/ncpcardio0583.CrossRefPubMed
30.
go back to reference Marfella R, Esposito K, Nappo F, Siniscalchi M, Sasso FC, Portoghese M, Di Marino MP, Baldi A, Cuzzocrea S, Di Filippo C, Barboso G, Baldi F, Rossi F, D'Amico M, Giugliano D: Expression of angiogenic factors during acute coronary syndromes in human type 2 diabetes. Diabetes. 2004, 53: 2383-2391. 10.2337/diabetes.53.9.2383.CrossRefPubMed Marfella R, Esposito K, Nappo F, Siniscalchi M, Sasso FC, Portoghese M, Di Marino MP, Baldi A, Cuzzocrea S, Di Filippo C, Barboso G, Baldi F, Rossi F, D'Amico M, Giugliano D: Expression of angiogenic factors during acute coronary syndromes in human type 2 diabetes. Diabetes. 2004, 53: 2383-2391. 10.2337/diabetes.53.9.2383.CrossRefPubMed
31.
go back to reference Talukder MA, Kalyanasundaram A, Zuo L, Velayutham M, Nishijima Y, Periasamy M, Zweier JL: Is reduced SERCA2a expression detrimental or beneficial to postischemic cardiac function and injury? Evidence from heterozygous SERCA2a knockout mice. Am J Physiol Heart Circ Physiol. 2008, 294: H1426-H1434.CrossRefPubMed Talukder MA, Kalyanasundaram A, Zuo L, Velayutham M, Nishijima Y, Periasamy M, Zweier JL: Is reduced SERCA2a expression detrimental or beneficial to postischemic cardiac function and injury? Evidence from heterozygous SERCA2a knockout mice. Am J Physiol Heart Circ Physiol. 2008, 294: H1426-H1434.CrossRefPubMed
32.
go back to reference Bugger H, Abel ED: Molecular mechanisms for myocardial mitochondrial dysfunction in the metabolic syndrome. Clin Sci. 2008, 114: 195-210. 10.1042/CS20070166.CrossRefPubMed Bugger H, Abel ED: Molecular mechanisms for myocardial mitochondrial dysfunction in the metabolic syndrome. Clin Sci. 2008, 114: 195-210. 10.1042/CS20070166.CrossRefPubMed
33.
go back to reference Hwang YC, Sato S, Tsai JY, Yan S, Bakr S, Zhang H, Oates PJ, Ramasamy R: Aldosereductase activation is a key component of myocardial response to ischemia. FASEB J. 2002, 16: 243-245.CrossRefPubMed Hwang YC, Sato S, Tsai JY, Yan S, Bakr S, Zhang H, Oates PJ, Ramasamy R: Aldosereductase activation is a key component of myocardial response to ischemia. FASEB J. 2002, 16: 243-245.CrossRefPubMed
34.
go back to reference Kaneko M, Bucciarelli L, Hwang YC, Lee L, Yan SF, Schmidt AM, Ramasamy R: Aldosereductase and AGE-RAGE pathways: key players in myocardial ischemic injury. Ann N Y Acad Sci. 2005, 1043: 702-709. 10.1196/annals.1333.081.CrossRefPubMed Kaneko M, Bucciarelli L, Hwang YC, Lee L, Yan SF, Schmidt AM, Ramasamy R: Aldosereductase and AGE-RAGE pathways: key players in myocardial ischemic injury. Ann N Y Acad Sci. 2005, 1043: 702-709. 10.1196/annals.1333.081.CrossRefPubMed
35.
go back to reference McGaffin KR, Sun CK, Rager JJ, Romano LC, Zou B, Mathier MA, O'Doherty RM, McTiernan CF, O'Donnell CP: Leptin signalling reduces the severity of cardiac dysfunction and remodelling after chronic ischaemic injury. Cardiovasc Res. 2008, 77: 54-63.CrossRefPubMed McGaffin KR, Sun CK, Rager JJ, Romano LC, Zou B, Mathier MA, O'Doherty RM, McTiernan CF, O'Donnell CP: Leptin signalling reduces the severity of cardiac dysfunction and remodelling after chronic ischaemic injury. Cardiovasc Res. 2008, 77: 54-63.CrossRefPubMed
36.
go back to reference McGaffin KR, Zou B, McTiernan CF, O'Donnell CP: Leptin attenuates cardiac apoptosis after chronic ischaemic injury. Cardiovasc Res. 2009, 83: 313-324. 10.1093/cvr/cvp071.PubMedCentralCrossRefPubMed McGaffin KR, Zou B, McTiernan CF, O'Donnell CP: Leptin attenuates cardiac apoptosis after chronic ischaemic injury. Cardiovasc Res. 2009, 83: 313-324. 10.1093/cvr/cvp071.PubMedCentralCrossRefPubMed
37.
go back to reference Van den Bergh A, Vangheluwe P, Vanderper A, Carmeliet P, Wuytack F, Janssens S, Flameng W, Holvoet P, Herijgers P: Food-restriction in obese dyslipidaemic diabetic mice partially restores basal contractility but not contractile reserve. Eur J Heart Fail. 2009, 11: 1118-1125. 10.1093/eurjhf/hfp156.CrossRefPubMed Van den Bergh A, Vangheluwe P, Vanderper A, Carmeliet P, Wuytack F, Janssens S, Flameng W, Holvoet P, Herijgers P: Food-restriction in obese dyslipidaemic diabetic mice partially restores basal contractility but not contractile reserve. Eur J Heart Fail. 2009, 11: 1118-1125. 10.1093/eurjhf/hfp156.CrossRefPubMed
38.
go back to reference Mitchell JR, Verweij M, Brand K, van de Ven M, Goemaere N, van den Engel S, Chu T, Forrer F, Müller C, de Jong M, van IJcken W, IJzermans JN, Hoeijmakers JH, de Bruin RW: Short-term dietaryrestriction and fasting precondition against ischemia reperfusion injury in mice. Aging Cell. 2010, 9: 40-53. 10.1111/j.1474-9726.2009.00532.x.PubMedCentralCrossRefPubMed Mitchell JR, Verweij M, Brand K, van de Ven M, Goemaere N, van den Engel S, Chu T, Forrer F, Müller C, de Jong M, van IJcken W, IJzermans JN, Hoeijmakers JH, de Bruin RW: Short-term dietaryrestriction and fasting precondition against ischemia reperfusion injury in mice. Aging Cell. 2010, 9: 40-53. 10.1111/j.1474-9726.2009.00532.x.PubMedCentralCrossRefPubMed
39.
go back to reference Yamagishi T, Bessho M, Yanagida S, Nishizawa K, Kusuhara M, Ohsuzu F, Tamai S: Severe, short-term food restriction improves cardiac function following ischemia/reperfusion in perfused rat hearts. Heart Vessels. 2010, 25: 417-425. 10.1007/s00380-009-1222-6.CrossRefPubMed Yamagishi T, Bessho M, Yanagida S, Nishizawa K, Kusuhara M, Ohsuzu F, Tamai S: Severe, short-term food restriction improves cardiac function following ischemia/reperfusion in perfused rat hearts. Heart Vessels. 2010, 25: 417-425. 10.1007/s00380-009-1222-6.CrossRefPubMed
40.
go back to reference Takeishi Y, Bhagwat A, Ball NA, Kirkpatrick DL, Periasamy M, Walsh RA: Effect of angiotensin-converting enzyme inhibition on protein kinase C and SR proteins in heart failure. Am J Physiol Heart Circ Physiol. 1999, 276: H53-H62. Takeishi Y, Bhagwat A, Ball NA, Kirkpatrick DL, Periasamy M, Walsh RA: Effect of angiotensin-converting enzyme inhibition on protein kinase C and SR proteins in heart failure. Am J Physiol Heart Circ Physiol. 1999, 276: H53-H62.
41.
go back to reference Gross ML, Heiss N, Weckbach M, Hansen A, El-Shakmak A, Szabo A, Münter K, Ritz E, Amann K: ACE-inhibition is superior to endothelin A receptor blockade in preventing abnormal capillary supply and fibrosis of the heart in experimental diabetes. Diabetologia. 2004, 47: 316-324. 10.1007/s00125-003-1309-z.CrossRefPubMed Gross ML, Heiss N, Weckbach M, Hansen A, El-Shakmak A, Szabo A, Münter K, Ritz E, Amann K: ACE-inhibition is superior to endothelin A receptor blockade in preventing abnormal capillary supply and fibrosis of the heart in experimental diabetes. Diabetologia. 2004, 47: 316-324. 10.1007/s00125-003-1309-z.CrossRefPubMed
42.
go back to reference Ren L, Liu N, Zhi H, Li Y, Li Y, Tang R, Sheng Z: Vasculoprotective effects of rosiglitazone through modulating renin-angiotensin system in vivo and vitro. Cardiovasc Diabetol. 2011, 10: 10-10.1186/1475-2840-10-10.PubMedCentralCrossRefPubMed Ren L, Liu N, Zhi H, Li Y, Li Y, Tang R, Sheng Z: Vasculoprotective effects of rosiglitazone through modulating renin-angiotensin system in vivo and vitro. Cardiovasc Diabetol. 2011, 10: 10-10.1186/1475-2840-10-10.PubMedCentralCrossRefPubMed
43.
go back to reference Ichinomiya T, Cho S, Higashijima U, Matsumoto S, Maekawa T, Sumikawa K: High-dose fasudil preserves postconditioning against myocardial infarction under hyperglycemia in rats: role of mitochondrial KATP channels. Cardiovasc Diabetol. 2012, 11: 28-10.1186/1475-2840-11-28.PubMedCentralCrossRefPubMed Ichinomiya T, Cho S, Higashijima U, Matsumoto S, Maekawa T, Sumikawa K: High-dose fasudil preserves postconditioning against myocardial infarction under hyperglycemia in rats: role of mitochondrial KATP channels. Cardiovasc Diabetol. 2012, 11: 28-10.1186/1475-2840-11-28.PubMedCentralCrossRefPubMed
Metadata
Title
Angiotensin-converting enzyme inhibition and food restriction in diabetic mice do not correct the increased sensitivity for ischemia-reperfusion injury
Authors
Gerry Van der Mieren
Ines Nevelsteen
Annelies Vanderper
Wouter Oosterlinck
Willem Flameng
Paul Herijgers
Publication date
01-12-2012
Publisher
BioMed Central
Published in
Cardiovascular Diabetology / Issue 1/2012
Electronic ISSN: 1475-2840
DOI
https://doi.org/10.1186/1475-2840-11-89

Other articles of this Issue 1/2012

Cardiovascular Diabetology 1/2012 Go to the issue